3-羟基-4,4-二甲氧基-1-哌啶羧酸乙酯 | 83898-43-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 3-羟基-4,4-二甲氧基-1-哌啶羧酸乙酯
• 英文名称: ethyl 3-hydroxy-4,4-dimethoxypiperidine-1-carboxylate
• 英文别名: ethyl 3-hydroxy-4,4-dimethoxy-1-piperidinecarboxylate
• CAS: 83898-43-5
• 化学式: C₁₀H₁₉NO₅
• 分子量: 233.265
• InChiKey: WMFAMWJTLDIEKW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  68.2
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2933399090

反应信息

• 作为反应物：
  描述：

  3-羟基-4,4-二甲氧基-1-哌啶羧酸乙酯 在 盐酸 、 硫酸 、 palladium 10% on activated carbon 、 氢气 、 甲酸铵 、 三乙酰氧基硼氢化钠 、 sodium hydride 、 碳酸氢钠 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 16.75h， 生成 ethyl (-)-cis-4-amino-3-methoxy-1-piperidinecarboxylate
  参考文献：
  名称：

  Optimization of Pyrrolamide Topoisomerase II Inhibitors Toward Identification of an Antibacterial Clinical Candidate (AZD5099)

  摘要：

  AZD5099 (compound 63) is an antibacterial agent that entered phase 1 clinical trials targeting infections caused by Gram-positive and fastidious Gram-negative bacteria. It was derived from previously reported pyrrolamide antibacterials and a fragment-based approach targeting the ATP binding site of bacterial type II topoisomerases. The program described herein varied a 3-piperidine substituent and incorporated 4-thiazole substituents that form a seven-membered ring intramolecular hydrogen bond with a 5-position carboxylic acid. Improved antibacterial activity and lower in vivo clearances were achieved. The lower clearances were attributed, in part, to reduced recognition by the multidrug resistant transporter Mrp2. Compound 63 showed notable efficacy in a mouse neutropenic Staphylococcus aureus infection model. Resistance frequency versus the drug was low, and reports of clinical resistance due to alteration of the target are few. Hence, 63 could offer a novel treatment for serious issues of resistance to currently used antibacterials.

  DOI：

  10.1021/jm500462x
• 作为产物：
  描述：

  3-溴-4-氧代哌啶-1-甲酸乙酯 生成 3-羟基-4,4-二甲氧基-1-哌啶羧酸乙酯
  参考文献：
  名称：

  Novel N-(3-hydroxy-4-piperidinyl)benzamide derivatives

  摘要：

  小说N-(3-羟基-4-哌啶基)苯甲酰胺及其衍生物，所述化合物可用作胃肠系统运动的刺激剂。

  公开号：

  US04962115A1

文献信息

• [EN] SUBSTITUTED TRICYCLIC COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS TRICYCLIQUES SUBSTITUÉS ET LEURS PROCÉDÉS D'UTILISATION
  申请人：BAYER HEALTHCARE AG

  公开号：WO2009033581A1

  公开（公告）日：2009-03-19

  This invention relates to novel compounds and processes for their preparation, methods of treating diseases, particularly cancer, comprising administering said compounds, and methods of making pharmaceutical compositions for the treatment or prevention of disorders, particularly cancer.

  这项发明涉及新颖化合物及其制备方法，治疗疾病的方法，特别是癌症，包括给予这些化合物，以及制备用于治疗或预防疾病，特别是癌症的药物组合物的方法。
• [EN] ANTIBACTERIAL PIPERIDINE DERIVATIVES<br/>[FR] COMPOSÉS ANTIBACTÉRIENS DÉRIVÉS DE PIPÉRIDINE
  申请人：ASTRAZENECA AB

  公开号：WO2006087543A1

  公开（公告）日：2006-08-24

  (EN) Compounds of formula (I) and their pharmaceutically acceptable salts are described: Formula (I). Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.(FR) La présente invention décrit des composés de formule (I) ainsi que leurs sels de qualité pharmaceutique : Formule (I). La présente invention décrit en outre des procédés de synthèse desdits composés, des préparations pharmaceutiques les contenant, leur emploi en tant que médicaments et leur emploi dans le traitement d'infections bactériennes.

  公式（I）的化合物及其药用盐被描述：公式（I）。还描述了它们的制备方法、含有它们的药物组成物、作为药物的用途以及在治疗细菌感染中的用途。
• [EN] 2- (PIPERIDIN-1-YL) -4-AZOLYL-THIAZOLE-5-CARBOXYLIC ACID DERIVATIVES AGAINST BACTERIAL INFECTIONS<br/>[FR] DÉRIVÉS D'ACIDE 2-(PIPÉRIDIN-1-YL)-4-AZOLYL-THIAZOLE-5-CARBOXYLIQUE CONTRE LES INFECTIONS BACTÉRIENNES
  申请人：ASTRAZENECA AB

  公开号：WO2010067125A1

  公开（公告）日：2010-06-17

  Compounds of formula (I) and their pharmaceutically acceptable salts are described. Processes for their preparation, pharmaceutical compositions containing them, their use as medicaments and their use in the treatment of bacterial infections are also described.

  公式（I）的化合物及其药用盐已被描述。还描述了它们的制备过程、含有它们的药物组合物、它们作为药物的用途以及它们在治疗细菌感染中的用途。
• [EN] LUMINALLY-ACTING N-(PIPERIDIN-4-YL)BENZAMIDE DERIVATIVES<br/>[FR] DÉRIVÉS DE N-(PIPÉRIDIN-4-YL)BENZAMIDE À ACTION LUMINALE
  申请人：TAKEDA PHARMACEUTICALS CO

  公开号：WO2021225968A1

  公开（公告）日：2021-11-11

  Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein m, R1, R2, R3, R4, R5, R6, X1, X2, X3 and X4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders, and conditions associated with the 5-HT4 receptor.

  本公开涉及公式1的化合物及其在药学上可接受的盐，其中m、R1、R2、R3、R4、R5、R6、X1、X2、X3和X4在规范中有定义。本公开还涉及制备公式1化合物的材料和方法，包含它们的药物组合物，以及它们用于治疗与5-HT4受体相关的疾病、疾病和症状的用途。
• Materials and methods for the treatment of gastroesophageal reflux disease
  申请人：——

  公开号：US20020025970A1

  公开（公告）日：2002-02-28

  The subject invention provides novel compounds and compositions for the safe and effective treatment of gastroesophageal reflux and related conditions. In a preferred embodiment, the compositions of the subject invention comprise esterified cisapride derivatives. These compositions possess potent activity in treating gastroesophageal reflux disease and substantially reduce adverse effects associated with the administration of cisapride. These adverse effects include, but are not limited to, diarrhea, abdominal cramping and elevations of blood pressure and heart rate.

  本发明提供了用于安全有效治疗胃食管逆流及相关疾病的新型化合物和组合物。在一种优选实施方式中，本发明的组合物包括酯化的西沙普利德衍生物。这些组合物具有强大的活性，可用于治疗胃食管逆流病，并显著减少与西沙普利德治疗相关的不良反应。这些不良反应包括但不限于腹泻、腹部痉挛以及血压和心率升高。